GC Biopharma enters Phase 2 for COVID-19 mRNA vaccine, targets 2028 self-sufficiency
AI Summary- GC Biopharma received approval for a South Korean Phase 2 trial of GC4006A.
- Participants aged 19 to 85 will undergo dose and immunogenicity testing against an active control.
- GC Biopharma plans first dosing this year and a Phase 3 IND application in 2027.